Bridgeway Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History
Bought
Maintained
Sold
Other funds holding CAMP
Bridgeway Capital Management's CAMP Position: Q3 2026 in Review
Bridgeway Capital Management increased its CAMP4 Therapeutics (CAMP) stake by 118% in Q3 2026, buying an estimated $121K and bringing the position to 54,378 shares worth $220K. The position accounts for ﹤0.01% of the portfolio, ranked #996.
Bridgeway Capital Management first reported a position in CAMP in Q2 2025 and has held it in 6 quarters since. 69 funds tracked by Wall St. Rank hold CAMP as of Q3 2026.
- Bridgeway Capital Management held 54,378 shares of CAMP4 Therapeutics worth $220K as of Q3 2026.
- Bridgeway Capital Management bought 29,378 CAMP4 Therapeutics shares in Q3 2026, an estimated $121K.
- CAMP4 Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #996 holding.
- Bridgeway Capital Management first reported a position in CAMP4 Therapeutics in Q2 2025 and has held it in 6 quarters since.
- 69 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.